Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [De Novo Classifications](/submissions/MI/de-novo-classifications) → [21 CFR 866.2952](/submissions/MI/de-novo-classifications/866.2952) → QPO — Device To Preserve And Stabilize Relative Abundances Of Microbial Nucleic Acids In Clinical Samples

# QPO · Device To Preserve And Stabilize Relative Abundances Of Microbial Nucleic Acids In Clinical Samples

_Microbiology · 21 CFR 866.2952 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/de-novo-classifications/QPO

## Overview

- **Product Code:** QPO
- **Device Name:** Device To Preserve And Stabilize Relative Abundances Of Microbial Nucleic Acids In Clinical Samples
- **Regulation:** [21 CFR 866.2952](/submissions/MI/de-novo-classifications/866.2952)
- **Device Class:** 2
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

OMNIgene.GUT Dx is a device intended for the non-invasive collection of human fecal samples and the stabilization of DNA from the bacterial community for subsequent assessment of the microbiome profile by an assay validated for use with the device. The device consists of a collection tube with a tube top and pusher cap with a screw seal, a spatula or spoon for transferring fecal specimen, 2 mL of stabilizing liquid, and a stainless-steel mixing ball. It is designed to preserve the relative abundances of bacterial organisms in fecal specimens stored at room temperature (20-26°C) for up to 30 days.

## Classification Rationale

Class II (special controls). The device is classified under 21 CFR 866.2952 as a device to preserve and stabilize relative abundances of microbial nucleic acids in clinical samples.

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN200040](https://fda.innolitics.com/submissions/MI/de-novo-classifications/QPO/DEN200040.md) | OMNIgene GUT Dx | DNA Genotek, Inc. | Nov 3, 2021 | DENG |

## Top Applicants

- DNA Genotek, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/de-novo-classifications/QPO](https://fda.innolitics.com/submissions/MI/de-novo-classifications/QPO)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com